LEXICON PHARMACEUTICALS, INC. Tax Withholding Paid on Stock Awards
LEXICON PHARMACEUTICALS, INC. (LXRX) reported Tax Withholding Paid on Stock Awards of $2.84 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation · last filed 2026-08-06
- LEXICON PHARMACEUTICALS, INC. payment, tax withholding, share-based payment arrangement for the quarter ending 2026-06-30 was $0.00.
- LEXICON PHARMACEUTICALS, INC. payment, tax withholding, share-based payment arrangement for the quarter ending 2026-03-31 was $2.84M, a 397.03% increase year-over-year.
- LEXICON PHARMACEUTICALS, INC. payment, tax withholding, share-based payment arrangement for the quarter ending 2025-12-31 was $0.00.
- LEXICON PHARMACEUTICALS, INC. payment, tax withholding, share-based payment arrangement for the quarter ending 2025-09-30 was $0.00.
- LEXICON PHARMACEUTICALS, INC. payment, tax withholding, share-based payment arrangement for fiscal 2025 was $572.00K, a 66.94% decline from fiscal 2024.
- LEXICON PHARMACEUTICALS, INC. payment, tax withholding, share-based payment arrangement for fiscal 2024 was $1.73M, a 109.95% increase from fiscal 2023.
- LEXICON PHARMACEUTICALS, INC. payment, tax withholding, share-based payment arrangement for fiscal 2023 was $824.00K.
| Period end | Payment, Tax Withholding, Share-based Payment Arrangement 3 month | Payment, Tax Withholding, Share-based Payment Arrangement 6 month | Payment, Tax Withholding, Share-based Payment Arrangement 9 month | Payment, Tax Withholding, Share-based Payment Arrangement 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $2.84M 10-Q · filed 2026-08-06 | $2.84M derived: sum of 3 quarters · filed 2026-08-06 | $2.84M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $2.84M 10-Q · filed 2026-05-07 | $2.84M derived: sum of 2 quarters · filed 2026-05-07 | $2.84M derived: sum of 3 quarters · filed 2026-05-07 | $2.84M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $0.00 derived: sum of 2 quarters · filed 2026-03-05 | $0.00 derived: sum of 3 quarters · filed 2026-08-06 | $572.00K 10-K · filed 2026-03-05 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2026-08-06 | $572.00K 10-Q · filed 2025-11-06 | $572.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $572.00K 10-Q · filed 2026-08-06 | $572.00K derived: sum of 3 quarters · filed 2026-08-06 | $572.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $572.00K 10-Q · filed 2026-05-07 | $572.00K derived: sum of 2 quarters · filed 2026-05-07 | $572.00K derived: sum of 3 quarters · filed 2026-05-07 | $572.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $0.00 derived: sum of 2 quarters · filed 2026-03-05 | $0.00 derived: sum of 3 quarters · filed 2026-03-05 | $1.73M 10-K · filed 2026-03-05 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | $1.73M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $1.73M 10-Q · filed 2025-08-06 | ||
| 2024-03-31 | $1.73M 10-Q · filed 2025-05-14 | |||
| 2023-12-31 | $824.00K 10-K · filed 2026-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |